Zevtera®

FDA Approves Basilea’s ZEVTERA® for Severe Bacterial Infections, Including Pediatric Use

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for…

1 month ago

Basilea Pharmaceutica Reports Strong H1 2023 Financial Results and Increases Full-Year Guidance

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced robust financial…

9 months ago

Shenzhen China Resources Gosun Pharmaceutical Co. granted exclusive license to develop, manufacture and to commercialize Basilea’s antibiotic Zevtera® (ceftobiprole) in China, Hong Kong and Macau

BASEL, 02-Oct-2017 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into…

7 years ago